Monograph Details
|
|
Eye Disorders
> Glaucoma
|
|
COMBIGAN |
| Manufacturer |
|
Allergan |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α2-agonist + noncardioselective β-blocker. |
| Generic Name |
|
Brimonidine tartrate 0.2%, timolol (as maleate) 0.5%; oph soln; contains benzalkonium chloride. |
| Indications |
|
To reduce elevated intraocular pressure (IOP) in glaucoma or ocular hypertension where adjunctive or replacement therapy is warranted. |
| Adults and Children |
|
<2yrs: not recommended. ≥2yrs: 1 drop every 12 hours. |
| Contraindications |
|
2nd or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock. Sinus bradycardia. Severe COPD. Bronchial asthma or history of. |
| Precautions |
|
Discontinue at 1st sign of cardiac failure and before surgery. Mild to moderate COPD, bronchospastic disease: not recommended. Depression. Cerebral or coronary insufficiency. Raynaud's phenomenon. Orthostatic hypotension. Thromboangiitis obliterans. Myasthenia gravis. Renal or hepatic impairment. May mask hypoglycemia, thyrotoxicosis. Soft contact lenses (remove; may reinsert 15 minutes after instillation). Separate dosing of other oph drugs by ≥5 minutes. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Avoid other topical β-blockers. May potentiate, or be potentiated by, other CNS depressants, systemic β-blockers, reserpine, quinidine, SSRIs, other CYP2D6 inhibitors. Caution with antihypertensives, systemic β-blockers, MAOIs, tricyclics. May cause conduction defects (eg, prolonged AV conduction) with digoxin, calcium channel blockers (avoid concomitant use in impaired cardiac function). May block systemic epinephrine. |
| Adverse Reactions |
|
Allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, pruritus, ocular burning/stinging, asthenia, corneal erosion, depression, epiphora, visual disturbance, headache, hypertension, dry mouth, somnolence, blepharitis, other local effects. |
| How Supplied |
|
Soln—5mL, 10mL, 15mL |
|
|
|
|
